Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARROW: Secukinumab vs Guselkumab in Ustekinumab-Resistant Psoriatic Plaques
2018-001048-70Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of secukinumab, guselkumab in plaque psoriasis, sponsored by Novartis. Started Aug 2018; status: completed.
02
Drugs
secukinumabguselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2018-001048-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001048-70.